Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats

Journal of Rheumatology

Volumn 26, Issue 6, 1999, Pages 1225-1229

  Bendele, Alison ^a,b   Sennello, Gina ^a   McAbee, Tracy ^a   Frazier, Jan ^a   Chlipala, Elizabeth ^a,b   Rich, Bill ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adjuvant arthritis; Interleukin 1; Interleukin 1 receptor antagonist; Methotrexate

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE;

ADJUVANT ARTHRITIS; ANIMAL MODEL; ANKLE; ARTICLE; BODY WEIGHT; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HISTOPATHOLOGY; JOINT FUNCTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PAW EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOOT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METHOTREXATE; ORGAN SIZE; RATS; RATS, INBRED LEW; SIALOGLYCOPROTEINS;

EID: 0032995904     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
2. Van de Loo FAJ, Arntz OJ, Otterness IG, van den Berg WB. Protection against cartilage proteoglycan synthesis inhibition by anti-interleukin-1 antibodies in experimental arthritis. J Rheumatol 1992;19:348-56.
3. Eastgate JA, Wood NC, di Giovine FS, Symons JA, Grinlinton JA, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988;24:706-9.
4. Khale P, Saal JG, Schaudt K. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 1992;51:731-4.
5. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-5.
6. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, and The IL-1ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1092-101.
7. Bresnihan B, Alvaro-Garcia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
8. Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20:190-9.
9. Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956;91:95-100.
10. Carlson RP, Datko LJ, O'Neil-Davis L, et al. Comparison of inflammatory changes in established type II collagen and adjuvant induced arthritis using outbred wistar rats. Int J Immunopharmacol 1985;7:811-26.
11. Benslay DN, Bendele AM. Development of a rapid screen for detecting and differentiating immunomodulatory vs. antiinflammatory compounds in rats. Agents Actions 1991;34:254-6.
12. Welles WL, Silknorth J, Oronsky AL, Kerwar SS, Galivan J. Studies on the effect of low dose methotrexate on rat adjuvant arthritis. J Rheumatol 1985;12:904-6.
13. Bendele AB, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Sustained blood levels of interleukin-1 receptor antagonist improve efficacy in animal models of arthritis: comparison of efficacy in animal models to human clinical data. Arthritis Rheum 1999; (in press).
14. van de Loo FAJ, Joosten LAB, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor α and interleukin-6 in cartilage proteoglycan metabolism and destruction. Arthritis Rheum 1995;38:164-72.
15. Kimble RB, Vannice JL, Bloedow DC, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 1994;93:1959-67.
16. Johnson WJ, DiMartino MJ, Meunier PC, Muirhead KA, Hanna N. Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol 1988;15:745-9.
17. Novaes GS, Mello SB, Laurindo IM, Cossermelli W. Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits. J Rheumatol 1996;23:2092-7.
18. Barrere P, Boerbooms AM, van de Putte LBA, van der Meer JWM. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996;25:234-53.
19. Walsdorfer U, Christophers E, Schroder JM. Methotrexate inhibits polymorphonuclear leucocyte chemotaxis in psoriasis. Br J Dermatol 1983;108:451-6.
20. Bendele AM, McComb J, Gould T, et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol 1999;27:134-42.
21. Brody M, Bohm I, Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1β to the interleukin receptor on target cells. Eur J Clin Chem Clin Biochem 1993;31:667-74.